Platforms for Manufacturing Allogeneic, Autologous and iPSC Cell Therapy Products: An Industry Perspective

As cell therapy processes mature from benchtop research protocols to industrial processes capable of manufacturing market-relevant numbers of doses, new cell manufacturing platforms are required. Here we give an overview of the platforms and technologies currently available to manufacture allogeneic...

Full description

Saved in:
Bibliographic Details
Published inAdvances in biochemical engineering, biotechnology Vol. 165; p. 323
Main Authors Abraham, Eytan, Ahmadian, Behnam Baghbaderani, Holderness, Kathryn, Levinson, Yonatan, McAfee, Erika
Format Journal Article
LanguageEnglish
Published Germany 01.01.2018
Subjects
Allogeneic
Autologous
iPSCs
Cell therapy
CAR-T
Mesenchymal stem cells
Online AccessGet more information

Cover

More Information
Summary:As cell therapy processes mature from benchtop research protocols to industrial processes capable of manufacturing market-relevant numbers of doses, new cell manufacturing platforms are required. Here we give an overview of the platforms and technologies currently available to manufacture allogeneic cell products, such as mesenchymal stem cells (MSCs) and induced pluripotent stem cells (iPSCs), and technologies for mass production of autologous cell therapies via scale-out. These technologies include bioreactors, microcarriers, cell separation and cryopreservation equipment, molecular biology tools for iPSC generation, and single-use controlled-environment systems for autologous cell production. These platforms address the challenges of manufacturing cell products in greater numbers while maintaining process robustness and product quality.
ISSN:0724-6145
DOI:10.1007/10_2017_14